ArticleNPJ digital medicine2026
A lightweight CVTC model for accurate Alzheimer's MRI analysis and lesion annotation.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In clinical practice, MRI images are widely used to diagnose neurodegenerative diseases like Alzheimer's disease (AD). However, complex MRI patterns often mimic normal aging, relying on subjective experience and risking misdiagnosis. This paper proposes the Cross Vision Transformer with Coordinate (CVTC) to assess AD severity and accurately annotate suspicious lesions, reducing clinicians' burden and improving reliability. CVTC integrates scale-adaptive embedding, dynamic position bias, and long-short attention mechanisms to enhance capture of local and global MRI features. For annotation, the Coordinate and Feature Map Guided Mechanism (CAGM) leverages pixel coordinates and feature maps to compute an importance threshold, generating lesion overlay maps for precise localization. A user-friendly UI is developed to enable intuitive exploration and validation in clinical settings. CVTC demonstrates robust performance across datasets: 98.80% accuracy on ADNI (AD/MCI/CN), 98.51% on AD subtypes (EMCI/LMCI/SMC/CN); cross-dataset validation on tumor and multiple sclerosis MRIs confirms CAGM's annotation accuracy; NACC (96.30%), OASIS-1 (98.16%), and pseudo-RGB datasets (92.96%) highlight superior generalization. Ablation and cross-validation affirm robustness. With a 21.850MB lightweight design, CVTC offers an efficient, accurate tool for diverse clinical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.